Curtis Gale Oltmans - Net Worth and Insider Trading
Curtis Gale Oltmans Net Worth
The estimated net worth of Curtis Gale Oltmans is at least $593,609 dollars as of 2024-06-01. Curtis Gale Oltmans is the General Counsel of Array BioPharma Inc and owns about 15,021 shares of Array BioPharma Inc (ARRY) stock worth over $585,068. Curtis Gale Oltmans is also the SVP, General Counsel of Fulcrum Therapeutics Inc and owns about 1,088 shares of Fulcrum Therapeutics Inc (FULC) stock worth over $8,541. Details can be seen in Curtis Gale Oltmans's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Curtis Gale Oltmans has not made any transactions after 2021-06-28 and currently still holds the listed stock(s).
Transaction Summary of Curtis Gale Oltmans
Curtis Gale Oltmans Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Curtis Gale Oltmans owns 2 companies in total, including Avenue Therapeutics Inc (ATXI) , and Fulcrum Therapeutics Inc (FULC) .
Click here to see the complete history of Curtis Gale Oltmans’s form 4 insider trades.
Insider Ownership Summary of Curtis Gale Oltmans
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ATXI | Avenue Therapeutics Inc | 2021-04-01 | director |
| FULC | Fulcrum Therapeutics Inc | 2021-06-28 | SVP & General Counsel |
Curtis Gale Oltmans Latest Holdings Summary
Curtis Gale Oltmans currently owns a total of 2 stocks. Among these stocks, Curtis Gale Oltmans owns 15,021 shares of Array BioPharma Inc (ARRY) as of February 5, 2019, with a value of $585,068 and a weighting of 98.56%. Curtis Gale Oltmans also owns 1,088 shares of Fulcrum Therapeutics Inc (FULC) as of June 28, 2021, with a value of $8,541 and a weighting of 1.44%.
Latest Holdings of Curtis Gale Oltmans
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| ARRY | Array BioPharma Inc | 2019-02-05 | 15,021 | 38.95 | 585,068 |
| FULC | Fulcrum Therapeutics Inc | 2021-06-28 | 1,088 | 7.85 | 8,541 |
Holding Weightings of Curtis Gale Oltmans
Curtis Gale Oltmans Form 4 Trading Tracker
According to the SEC Form 4 filings, Curtis Gale Oltmans has made a total of 0 transactions in Array BioPharma Inc (ARRY) over the past 5 years. The most-recent trade in Array BioPharma Inc is the sale of 40,000 shares on February 5, 2019, which brought Curtis Gale Oltmans around $800,000.
According to the SEC Form 4 filings, Curtis Gale Oltmans has made a total of 1 transactions in Fulcrum Therapeutics Inc (FULC) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Fulcrum Therapeutics Inc is the acquisition of 1,088 shares on June 28, 2021, which cost Curtis Gale Oltmans around $9,803.
Insider Trading History of Curtis Gale Oltmans
- 1
Curtis Gale Oltmans Trading Performance
GuruFocus tracks the stock performance after each of Curtis Gale Oltmans's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Curtis Gale Oltmans is 206.99%. GuruFocus also compares Curtis Gale Oltmans's trading performance to market benchmark return within the same time period. The performance of stocks bought by Curtis Gale Oltmans within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Curtis Gale Oltmans's insider trading performs compared to the benchmark.
Performance of Curtis Gale Oltmans
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -14.54 | | | | | |
| Relative Return to S&P 500(%) | -17.1 | | | | | |
Curtis Gale Oltmans Ownership Network
Curtis Gale Oltmans Owned Company Details
What does Avenue Therapeutics Inc do?
Who are the key executives at Avenue Therapeutics Inc?
Curtis Gale Oltmans is the director of Avenue Therapeutics Inc. Other key executives at Avenue Therapeutics Inc include 10 percent owner Fortress Biotech, Inc. , 10 percent owner Invagen Pharmaceuticals, Inc. , and Chief Executive Officer Alexandra Maclean .
Avenue Therapeutics Inc (ATXI) Insider Trades Summary
Over the past 18 months, Curtis Gale Oltmans made no insider transaction in Avenue Therapeutics Inc (ATXI). Other recent insider transactions involving Avenue Therapeutics Inc (ATXI) include a net sale of 617,000 shares made by , a net purchase of 418,410 shares made by Fortress Biotech, Inc. , and a net purchase of 348,675 shares made by Rosenwald Lindsay A Md .
In summary, during the past 3 months, insiders sold 0 shares of Avenue Therapeutics Inc (ATXI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 8,227 shares of Avenue Therapeutics Inc (ATXI) were sold and 10,228 shares were bought by its insiders, resulting in a net purchase of 2,001 shares.
Avenue Therapeutics Inc (ATXI)'s detailed insider trading history can be found in Insider Trading Tracker table.
Avenue Therapeutics Inc Insider Transactions
Curtis Gale Oltmans Mailing Address
Above is the net worth, insider trading, and ownership report for Curtis Gale Oltmans. You might contact Curtis Gale Oltmans via mailing address: C/o Array Biopharma Inc., 3200 Walnut St., Boulder Co 80301.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
